BIND Therapeutics, Inc. is a clinical-stage nanomedicinal platform company that develops Accurins, a targeted and programmable therapy. The company had announced today its pricing for a proposed initial public offering of its shares of common stock. BIND Therapeutics offered 4,700,000 shares of common stock priced USD15 per share piece before underwriting discounts and commissions.
The company would start trading on September 20, 2013 at the NASDAQ under the trading symbol "BIND". The company had also granted underwriters a 30 day option to purchase additional shares of 705,000 common stock. This would be priced at the same value as the IPO set price to cover over-allotments, if any. The offer would close on September 25, 2013, subject to customary closing conditions.
BIND Therapeutics appointed Credit Suisse LLC and Cowen and Company LLC as acting joint book running manager for the initial public offer. Meanwhile, Stifel Nicolaus & Company and JMP Securities LLC were appointed as acting co-managers for the deal. The company had filed its registration statement and declared effective by the US Securities and Exchange Commission on September 19, 2013.
Join the Conversation